| Mr Brett Joseph Kieffer, AA-S | |
|
1255 Highway 54 W, Fayetteville, GA 30214-4526 | |
| (770) 719-7000 | |
| Not Available |
| Full Name | Mr Brett Joseph Kieffer |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 10 Years |
| Location | 1255 Highway 54 W, Fayetteville, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366864845 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 7308 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Fayette Hospital | Fayetteville, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Piedmont Anesthesia Associates Llc | 3577457183 | 260 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that it has entered into an agreement with Shionogi & Co. Ltd. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan.
Thickness of the cornea, the thin, transparent layer covering the eye, may be an important factor in considering treatment options for patients with glaucoma, according to an article appearing in the September issue of The Archives of Ophthalmology, one of the JAMA/Archives journals.
AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.
An interdisciplinary team of engineers at the University of Arkansas has developed a wireless health-monitoring system that gathers critical patient information, regardless of the patient's location, and communicates that information in real time to a physician, hospital or the patient herself.
› Verified 6 days ago
| Entity Name | Piedmont Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407856594 PECOS PAC ID: 3577457183 Enrollment ID: O20040212000604 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that it has entered into an agreement with Shionogi & Co. Ltd. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan.
Thickness of the cornea, the thin, transparent layer covering the eye, may be an important factor in considering treatment options for patients with glaucoma, according to an article appearing in the September issue of The Archives of Ophthalmology, one of the JAMA/Archives journals.
AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.
An interdisciplinary team of engineers at the University of Arkansas has developed a wireless health-monitoring system that gathers critical patient information, regardless of the patient's location, and communicates that information in real time to a physician, hospital or the patient herself.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Brett Joseph Kieffer, AA-S 1255 Highway 54 W, Fayetteville, GA 30214-4526 Ph: (770) 719-7000 | Mr Brett Joseph Kieffer, AA-S 1255 Highway 54 W, Fayetteville, GA 30214-4526 Ph: (770) 719-7000 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that it has entered into an agreement with Shionogi & Co. Ltd. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan.
Thickness of the cornea, the thin, transparent layer covering the eye, may be an important factor in considering treatment options for patients with glaucoma, according to an article appearing in the September issue of The Archives of Ophthalmology, one of the JAMA/Archives journals.
AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.
An interdisciplinary team of engineers at the University of Arkansas has developed a wireless health-monitoring system that gathers critical patient information, regardless of the patient's location, and communicates that information in real time to a physician, hospital or the patient herself.
› Verified 6 days ago
Danielle Duncan, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1255 Highway 54 W, Fayetteville, GA 30214 Phone: 770-719-7000 | |
Callie Kennedy, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1255 Highway 54 W, Fayetteville, GA 30214 Phone: 770-719-7000 | |
Mr. Hugh Duggan, MS IN ANESTHESIA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1255 Highway 54 W, Fayetteville, GA 30214 Phone: 770-719-7000 | |
David P Wright, PA-AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1255 Highway 54 W, Fayetteville, GA 30214 Phone: 404-351-1745 Fax: 404-351-7121 | |
Joshua Gordon, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1255 Ga-54, Fayetteville, GA 30214 Phone: 770-719-7000 | |
Mrs. Maria Magdalena Earnhart, Anesthesiologist Assistant Medicare: May Accept Medicare Assignments Practice Location: 1255 Highway 54 W, Fayetteville, GA 30214 Phone: 770-719-7000 |